On CNBC's “Mad Money Lightning Round,” Jim Cramer believes in Moderna, Inc. MRNA.
On May 14, Evercore ISI Group analyst Cory Kasimov initiated coverage on Moderna with an In-Line rating and announced a price target of $120.
The “Mad Money” host likes Mind Medicine (MindMed) Inc. MNMD. “Anything that makes it so that there's ways to be able to get rid of pain and do good without getting people hooked, I am all in on. Doesn't necessarily mean it will make a lot of money, I don't care,” he added.
On May 13, Oppenheimer analyst Francois Brisebois reiterated Mind Medicine with an Outperform and lowered the price target from $29 to $20.
“I don't want you to sell, and I don't want you to double down,” Cramer said when asked about Hertz Global Holdings, Inc. HTZ. “Let's just see if it can't go higher.”
On April 25, Hertz Global reported mixed first-quarter financial results.
Cramer recommended buying Modine Manufacturing Company MOD. “That kind of metal-bending industrial company is precisely what's working here,” he added.
Modine is scheduled to host a conference call and webcast to discuss its fourth quarter and fiscal year 2024 financial results on Wednesday, May 22.
AMETEK, Inc. AME is a buy, Cramer said. It is an “absolutely terrific” company.
On May 2, AMETEK reported worse-than-expected first-quarter sales results.
When asked about Palantir Technologies Inc. PLTR, he said, “The quarters are uneven.”
On May 6, Palantir said first-quarter revenue increased 21% year-over-year to $634 million, which beat the consensus estimate of $625.431 million, according to Benzinga Pro.
Price Action:
- Moderna shares rose 2.1% to settle at $128.32 on Tuesday.
- MindMed shares rose 0.5% to close at $8.49.
- Modine Manufacturing shares rose 4.4% to settle at $105.66 on Tuesday.
- AMETEK shares fell 0.9% to settle at $168.53.
- Hertz shares rose 9.7% to close at $6.00 on Tuesday.
- Palantir shares rose 2.4% to settle at $21.44 on Tuesday.
Read Next: Cisco, Prestige Consumer Healthcare And 3 Stocks To Watch Heading Into Wednesday
Image: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
